Full Text View
Tabular View
No Study Results Posted
Related Studies
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
This study is currently recruiting participants.
Verified January 2013 by National Institutes of Health Clinical Center (CC)
Study NCT00923013   Information provided by National Institutes of Health Clinical Center (CC)

First Received on June 17, 2009.   Last Updated on June 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hairy Cell Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Hairy Cell
Neoplasm, Residual
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
Cladribine
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services